Caris Life Sciences, Inc. (CAI) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 5 Buy, 1 Hold.
The consensus price target is $31.33 (low: $26.00, high: $38.00), representing an upside of 55.2% from the current price $20.19.
Analysts estimate Earnings Per Share (EPS) of $-10.43 and revenue of $0.45B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.70 vs est $-10.43 (beat +74.1%). 2025: actual $-1.90 vs est $-1.06 (missed -79.3%). Analyst accuracy: 0%.
CAI Stock — 12-Month Price Forecast
$31.33
▲ +55.18% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Caris Life Sciences, Inc., the average price target is $31.33, with a high forecast of $38.00, and a low forecast of $26.00.
The average price target represents a +55.18% change from the last price of $20.19.
Highest Price Target
$38.00
Average Price Target
$31.33
Lowest Price Target
$26.00
CAI Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Caris Life Sciences, Inc. in the past 3 months
EPS Estimates — CAI
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.70
vs Est –$10.43
▲ 286.4% off
2025
Actual –$1.90
vs Est –$1.06
▼ 44.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CAI
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.412B
vs Est $0.452B
▼ 9.8% off
2025
Actual $0.812B
vs Est $0.760B
▲ 6.5% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
